NON-HODGKIN'S LYMPHOMA

This study tests whether adding the drug acalabrutinib to standard chemotherapy can cure more people with untreated diffuse large B-cell lymphoma, an aggressive blood cancer. About 132 adults will take the pill twice daily for up to 14 days, then receive standard chemo and rituxi…

This study tests whether a combination of three drugs (etoposide, cytarabine, and PEG-rhG-CSF) can collect more stem cells for transplant in people with non-Hodgkin's lymphoma. About 99 patients who are in remission will be randomly assigned to receive either the new combo or sta…

This study tests a new way to make special immune cells (T cells) that can attack cancer cells infected with the Epstein-Barr virus (EBV). The cells are grown faster in the lab and given to patients with Hodgkin or non-Hodgkin lymphoma, or related diseases that have come back or …

This early-phase trial tests a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or not responded to standard therapy. CLIC-2201 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cell…

This early-phase trial tests an experimental drug called GNC-035 in 40 adults with non-Hodgkin lymphoma that has come back or stopped responding to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. GNC-035 is a tetra-specific antibody …

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This early-stage study tests a new drug, ABBV-291, in adults with Non-Hodgkin's lymphoma that has returned or not responded to treatment. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 165 participants will receive the drug throu…

This study is testing an improved method for cord blood transplants in adults with high-risk blood cancers like leukemia and lymphoma. The goal is to see if this optimized approach helps patients live longer and have fewer side effects. About 54 participants will receive the tran…

This study tests a new drug called GNC-038, a special antibody that targets cancer from four different angles. It is for people with Non-Hodgkin's lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find …

This study compares two common treatments—immunoglobulin and antibiotics—to see which is better at preventing serious infections in people with blood cancers like myeloma, lymphoma, or leukemia. About 900 adults will take part. The goal is to find the safest and most effective wa…

This study aims to understand why some families have multiple members with lymphoma or related blood cancers. Researchers will collect tumor samples and health information from 1,500 participants to look for unique genetic changes. The goal is to identify genes that may increase …

This study is collecting medical information from 2,000 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. The goal is to create a new tool that helps doctors predict which patients are at higher or lower risk, so they can choose the best trea…

This study gathers basic survival and complication information from 2000 people receiving stem cell transplants for blood cancers or immune diseases. The goal is to build a database for future research and to improve patient care. No new treatments are being tested; only standard…

This study is a large registry that gathers medical information and biological samples from 10,000 adults with acute lymphoblastic leukemia (ALL) and similar blood cancers. The goal is to learn how these diseases are diagnosed and treated in everyday practice, and to track patien…